Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report

Figure 4 Pathological and gene alteration analyses of the two biopsies. Amplification refractory mutation system-polymerase chain reaction test only detected exon 19 deletion in both samples (A), whereas next-generation sequencing detected the presence of an EGFR T790M mutation in addition to the exon 19-deletion mutation (p.E746_A750del) of the re-biopsy sample (B). NGS: Next-generation sequencing; ARMS-PCR: Amplification refractory mutation system-polymerase chain reaction.